The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

We believe that over the next 5–10 years new anti-obesity drugs with less adverse side-effects and favorable effects on both lipids and cardiometabolic risk will be introduced in clinical practice.

Obesity continues to plague New ... only significant for those currently taking these drugs but also for the social and fiscal health of New York City and our entire state. The city claims that ...

But a new proposal announced by the Biden administration in November ... But it also comes with a price tag in the tens of ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

The development of anti-obesity drugs like GLP-1 receptor agonists addresses ... there is a high demand for new and innovative solutions.

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...